News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Japan's Eisai Company, Ltd. (ESALY.PK) Buys Rights to Alzheimer's Antibody from BioArctic Neuroscience AB


12/4/2007 7:26:53 AM

Dec. 4 (Bloomberg) -- Eisai Co. bought the rights to an experimental Alzheimer's disease treatment from BioArctic Neuroscience AB, giving the Japanese drugmaker another potential successor to its best-seller, Aricept. Eisai, Japan's fourth-largest drugmaker, has the global rights to study, develop, manufacture and market the drug, known as BAN2401, under an agreement signed yesterday with Stockholm- based BioArctic Neuroscience. No financial terms were disclosed.

Read at Reuters
Read at Bloomberg


comments powered by Disqus
Reuters
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES